PRDX6 and cancer: employed two independent cohorts to study a panel of six autoantibodies against p53, NY-ESO-1, MMP-7, HSP70, PRDX-6, and BMI-1 and found that a single cancer-associated autoantibody biomarker has limited diagnostic value (33).